Cart
sales@molnova.com
ST7612AA1
CAS No. 1428535-92-5
ST7612AA1( —— )
Catalog No. M36350 CAS No. 1428535-92-5
ST7612AA1 is a novel potent and oral HDCA inhibitor that acts as an HIV-1 latency reactivator. ST7612AA1 showed significant antitumor activity at low concentrations in vitro and in vivo.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 459 | In Stock |
|
| 10MG | 657 | In Stock |
|
| 25MG | 1026 | In Stock |
|
| 50MG | 1386 | In Stock |
|
| 100MG | 1832 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 3655 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameST7612AA1
-
NoteResearch use only, not for human use.
-
Brief DescriptionST7612AA1 is a novel potent and oral HDCA inhibitor that acts as an HIV-1 latency reactivator. ST7612AA1 showed significant antitumor activity at low concentrations in vitro and in vivo.
-
DescriptionST7612AA1 is a novel potent and oral HDCA inhibitor that acts as an HIV-1 latency reactivator. ST7612AA1 showed significant antitumor activity at low concentrations in vitro and in vivo. ST7612AA1 has potential anticancer activity and can be used to study malaria.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV Protease
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1428535-92-5
-
Formula Weight405.51
-
Molecular FormulaC20H27N3O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(N[C@H](C(NC1=CC=CC=C1)=O)CCCCCSC(C)=O)(=O)[C@@H]2NC(=O)CC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Tripterifordin
Tripterifordin shows anti-HIV replication activity in H9 lymphocyte cells with an EC50 of 1 microgram/ml.
-
NBD-14189
NBD-14189 (NBD14189) is a novel potent HIV-1 entry antagonist with potency as low as 63?nM against some clinical isolates.
-
BNM-III-170
BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo.
